Biomarker ID | 280 |
PMID | 18543251 |
Year | 2008 |
Biomarker | Golgi phosphoprotein 2 (GOLPH2) |
Biomarker Basis | Expression Based |
Biomolecule | mRNA |
Source | Tissue |
Subjects | Humans |
Regulation | Upregulated in Prostate Cancer(3.04 fold) |
Odds Ratio/Hazard Ratio/Relative Risk | NA |
Effect on Pathways | Pathways Include:-TGF-beta regulation of extracellular matrix |
Experiment | prostate cancer Vs normal prostate |
Type of Biomarker | Diagnostic |
Cohort | 30 normal tissue samples compared with 30 cancerous tissue samples using RT-PCR. 5 normal tissue samples compared with 5 cancerous tissue samples using Western Blot Analysis. |
Senstivity | NA |
Specificity | NA |
AUC | NA |
Accuracy | NA |
Level Of Significance | p<0.001 |
Method Used | RT-PCR |
Clinical | No |
Remarks | Molecular alterations associated with the Golgi apparatus may take place during prostate carcinogenesis. |
Clinical Trial Number | NA |
Degree Of Validity | Validated on Independent Patient Dataset |
Technical Name | GOLM1 |